U.S. Life Sciences Stock News

NYSE:UVV
NYSE:UVVTobacco

Universal (UVV) Margin Compression And One Off Loss Test Bullish Growth Narratives

Universal (NYSE:UVV) FY 2026 Earnings Snapshot Universal (NYSE:UVV) closed out FY 2026 with Q4 revenue of US$715.2 million and a reported loss per share of US$1.73, as investors weighed these headline figures against full year trends. Over the past six quarters, revenue has moved between US$593.8 million and US$937.2 million per quarter, while quarterly EPS ranged from US$0.34 to US$2.39 before this latest loss. This gives you a wide band of outcomes to factor into your view on the stock...
NYSE:HII
NYSE:HIIAerospace & Defense

Is It Too Late To Consider Huntington Ingalls Industries (HII) After The Recent Pullback?

Wondering whether Huntington Ingalls Industries, at around US$308 a share, still offers value or if most of the opportunity has already been priced in. The stock is down 3.9% over the past week and 14.9% over the past month, yet it still shows a 40.5% return over 1 year and 58.2% over 3 years, which can change how you think about both risk and opportunity. Recent coverage has focused on Huntington Ingalls Industries as a key US defense contractor, with attention on its role in major long...
NasdaqGS:OKTA
NasdaqGS:OKTAIT

Okta (OKTA) Margin Expansion Reinforces Bullish Profitability Narratives In Q1 2027

Q1 2027 earnings set the stage Okta (OKTA) has just opened Q1 2027 with revenue of US$765 million and basic EPS of US$0.42, putting fresh numbers behind a year in which trailing EPS reached US$1.40 on US$3.0 billion of revenue and net income of US$247 million. Over the past six reported quarters, revenue has moved from US$682 million in Q4 2025 to US$765 million in Q1 2027, while quarterly basic EPS has ranged between US$0.13 and US$0.42. This gives investors a clearer picture of how profit...
NYSE:EMN
NYSE:EMNChemicals

Is Eastman Chemical (EMN) Offering Value After Recent Share Price Rebound?

Wondering if Eastman Chemical at around US$75.87 is offering real value or just fair pricing? This article walks through what the numbers say about the stock. The share price return sits at 2.4% over the past week, 7.7% over the past month, 17.9% year to date and 1.6% over the past year, against a longer-term picture that includes a 3.5% return over three years and a decline of 29.7% over five years. Recent coverage has focused on Eastman Chemical's role as a diversified materials producer,...
NYSE:COUR
NYSE:COURConsumer Services

Is Coursera (COUR) Offering Value After Recent Share Price Weakness And Growth Partnership Focus

Wondering whether Coursera at US$5.39 is starting to look like value, or if the stock still carries more risk than reward. The share price has inched up about 1.3% over the last week, but is still down about 11.8% over the past month, 23.9% year to date and 39.1% over the last year, which may catch the eye of investors looking for a reset opportunity. Recent headlines have focused on Coursera's position as a major online learning platform and its role in digital upskilling partnerships. This...
NYSE:LOB
NYSE:LOBBanks

Is It Time To Reconsider Live Oak Bancshares (LOB) After Its 39% One Year Run?

Wondering whether Live Oak Bancshares at around US$38.03 is offering fair value right now, or if the recent price puts it out of your comfort zone? The stock has returned 2.0% over the past week, 0.6% over the last month, 9.6% year to date and 39.0% over the past year, while the 5 year return shows a decline of 32.9%. These moves have come as Live Oak Bancshares continues to attract attention in the US regional banking space, with investors watching how its lending focus and digital platform...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics' BRIUMVI Data Supports Simplified Regimen And Valuation Upside

TG Therapeutics reported positive Phase 3 ENHANCE results for BRIUMVI, confirming a single 600 mg Day 1 infusion is bioequivalent to the current two-infusion initiation regimen for multiple sclerosis. The simplified regimen is intended to reduce treatment burden for patients and infusion centers while maintaining safety and efficacy outcomes seen in the trial. The company plans to submit these data to regulators, aiming to update the BRIUMVI label pending review and approval. For investors...
NasdaqGS:CDNS
NasdaqGS:CDNSSoftware

Cadence Samsung 2nm Alliance Deepens Role In Next Generation AI Design

Cadence Design Systems (NasdaqGS:CDNS) and Samsung Foundry agreed a multi-year expansion of their collaboration around second-generation 2nm process technology. The deal covers a broad Memory and Interface IP portfolio and certification of Cadence's AI focused design and analysis flows across Samsung's next generation 2nm and 3D IC platforms. The partnership targets next generation AI infrastructure and hardware, aiming to provide a more complete platform for advanced chip design. For...
NasdaqGS:TRMK
NasdaqGS:TRMKBanks

Trustmark Retail Banking Leadership Change And What It Means For Investors

Trustmark (NasdaqGS:TRMK) announced the retirement of Wayne A. Stevens as President of Retail Banking. Stevens concludes a career of more than four decades with the company, including service as an executive officer since 2009. The change affects leadership of one of Trustmark’s core business areas, retail banking. For a regional financial institution like Trustmark, retail banking sits at the heart of its business model, connecting deposit customers, consumer lending and local branch...
NasdaqGS:ISRG
NasdaqGS:ISRGMedical Equipment

Intuitive Surgical Ties Da Vinci 5 Upgrades To Global Growth Push

Intuitive Surgical (NasdaqGS:ISRG) is rolling out more than 100 upgrades to its da Vinci 5 robotic surgery platform, including extended-use Force Feedback instruments aimed at reducing per procedure costs. The company has also promoted Taylor Patton to Chief Commercial and Marketing Officer, positioning her to lead global commercialization efforts for da Vinci 5 and other platforms. For anyone following surgical robotics, Intuitive Surgical sits at the center of one of the most closely...
NasdaqGS:ARXS
NasdaqGS:ARXSAerospace & Defense

Arxis IPO, Record Quarter And Micro-Tronics Deal Shape Growth Path

Arxis, ticker NasdaqGS:ARXS, reported record first quarter financial results. The company completed its IPO and used proceeds to strengthen its balance sheet and fund future growth. Arxis acquired Micro-Tronics, adding aerospace and defense component capabilities. Arxis operates in markets tied to aerospace and defense components, areas that often rely on precision engineering, long product cycles, and high qualification standards. The record first quarter performance, combined with the...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Is It Too Late To Consider Guardant Health (GH) After A 246% One Year Surge?

If you are wondering whether Guardant Health at around US$133 is starting to look stretched or still offers value, this article walks through the key signals that may matter to you as a shareholder or potential buyer. The stock has logged returns of 12.9% over the past week, 60.3% over the past month, 30.9% year to date and 245.6% over the past year. This puts recent pricing firmly in focus for any valuation check. Recent coverage has highlighted Guardant Health as a high growth healthcare...
NasdaqGM:DAVE
NasdaqGM:DAVEConsumer Finance

Dave Joins S&P SmallCap 600 As Growth And Valuation Thesis Evolve

Dave Inc. (NasdaqGM:DAVE) is set to join the S&P SmallCap 600 Index, reflecting the company’s progress and growing presence in public markets. The index change is scheduled to take effect soon, positioning Dave alongside a broader group of small cap companies followed by institutional investors. Dave operates as a financial services platform, focusing on tools that help consumers manage cash flow and avoid common banking fees. Inclusion in the S&P SmallCap 600 Index brings the company into...
NYSE:RCL
NYSE:RCLHospitality

Is It Too Late To Consider Royal Caribbean Cruises (RCL) After Its Strong Share Price Run?

Wondering whether Royal Caribbean Cruises at around US$281 per share still offers value, or if most of the easy gains are already behind it. The stock has returned 8.1% over the past week and 9.9% over the last month, while year to date it is down 0.7% and the 1 year return sits at 12.2%, with a very large 3 year gain and a 203.8% return over 5 years. Recent headlines around Royal Caribbean Cruises have often focused on its share price strength and ongoing investor interest in the cruise...
NYSE:PLD
NYSE:PLDIndustrial REITs

Does Prologis (PLD) Still Offer Value After A 38% One-Year Share Price Gain?

If you are wondering whether Prologis stock still offers value at current levels, it helps to step back and separate price excitement from underlying worth. The stock last closed at US$145.64, with returns of 0.7% over 7 days, 2.9% over 30 days, 12.9% year to date and 38.0% over 1 year, which naturally raises questions about what is already reflected in the share price. Recent headlines around Prologis have focused on its role as a major industrial real estate player, including coverage of...
NYSE:XXI
NYSE:XXICapital Markets

Assessing Twenty One Capital (XXI) Valuation After A Steep Share Price Fall And Recent Rebound

Why Twenty One Capital is on investors’ radar Twenty One Capital (XXI) has drawn attention after a challenging year for the stock, with the share price down 82.6% over the past 12 months despite a market value of about US$2.5b. See our latest analysis for Twenty One Capital. At the current share price of US$7.33, the stock has seen a 90 day share price return of 27.7%, which only partially offsets the 1 year total shareholder return decline of 82.6%. This suggests that recent momentum is...
NYSE:SMR
NYSE:SMRElectrical

NuScale Power Targets AI Data Center Demand With NRC Approved SMRs

NuScale Power, NYSE:SMR, is highlighting its two separate U.S. Nuclear Regulatory Commission approvals as a key advantage for serving fast growing power needs from AI data centers and industrial users. The company is advancing commercial discussions that link its small modular reactor designs to long term electricity demand tied to AI infrastructure. This angle positions NuScale within the projected $10 trillion nuclear infrastructure opportunity connected to data center growth, an area...
NYSE:MC
NYSE:MCCapital Markets

How Investors May Respond To Moelis (MC) Earnings Miss Despite In-Line Revenue And Rising Cost Pressure

Earlier this year, Moelis & Company reported first-quarter revenue that matched analyst expectations but delivered earnings per share that fell well short of forecasts, highlighting higher-than-anticipated costs or margin pressure. This earnings miss came during a mixed quarter for independent advisers, where some peers exceeded both revenue and profit expectations, sharpening comparisons around Moelis’ efficiency and profitability. We’ll now explore how Moelis’ earnings shortfall, despite...
NasdaqGS:HUT
NasdaqGS:HUTSoftware

Hut 8 CEO Defends Beacon Point Plan As Stock Momentum Raises Stakes

Hut 8 CEO Asher Genoot publicly addressed community concerns about the Beacon Point AI data center campus, focusing on environmental and local impact. Genoot highlighted closed-loop cooling systems designed to reduce water use, along with planned community investments tied to the project. The CEO also outlined the financing structure for Beacon Point, describing it as a multibillion dollar flagship infrastructure project for Hut 8. For investors watching NasdaqGS:HUT, this update adds...
NasdaqGS:LX
NasdaqGS:LXConsumer Finance

LexinFintech (LX) Is Up 15.0% After Q1 2026 Earnings And Completed Buyback Program - Has The Bull Case Changed?

LexinFintech Holdings’ previously scheduled Q1 2026 earnings release and earnings call, held on May 25, 2026, have drawn fresh attention to the company’s latest operating performance and management commentary. Alongside completing a US$39 million buyback of 9,600,000 shares announced in July 2025, the earnings-focused news flow has renewed interest in LexinFintech’s capital return story and business outlook. Against this backdrop, we’ll examine how the Q1 2026 earnings call and completed...
NYSE:ASB
NYSE:ASBBanks

What Associated Banc-Corp (ASB)'s Dallas Commercial Expansion Means For Shareholders

In May 2026, Associated Banc-Corp moved to expand its commercial banking capabilities in Texas by building a dedicated Corporate and Commercial Banking team in Dallas, doubling its Preston Center office space, and hiring veteran banker Brandon White as senior vice president and Dallas market leader. This push extends the bank’s branch-light commercial model that it previously applied in Kansas City, aiming to deepen relationship-based lending and treasury services across fast-growing...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

High Growth Tech Stocks in US for May 2026

The United States market has shown robust performance, climbing 1.8% over the last week and 28% in the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on these positive trends.
NasdaqGS:ALKT
NasdaqGS:ALKTSoftware

Three Stocks That May Be Trading Below Estimated Value In May 2026

The United States market has shown robust growth, with a 1.8% increase over the last week and a remarkable 28% rise over the past year, while earnings are projected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future growth.
NYSE:CNC
NYSE:CNCHealthcare

Health Net Award Puts Centene’s Service Reputation And Valuation In Focus

Health Net, a subsidiary of Centene (NYSE:CNC), has been named one of America’s Best Customer Service providers in Financial Services for 2026. The recognition comes from USA TODAY and Plant-A Insights Group. Health Net is the only California-based health insurer to receive the top rating. For investors tracking NYSE:CNC, this recognition helps illustrate how the business operates in a highly regulated and competitive health insurance market. Centene focuses on government sponsored health...